Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Victoria's Secret & Co (VSXY) Price & Performance

Charles River Laboratories Intl. IncTrade
Victoria's Secret & CoTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Victoria's Secret & Co — how do they compare? Charles River Laboratories Intl. Inc trades at $228.88 (market cap $11.14B), while Victoria's Secret & Co trades at $84.72 (market cap $6.51B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap. Which is the better fit depends on your goals.

CRLVSXY
Market Cap
$11.14B$6.51B
Sector
HealthConsumer Cyclical
52-Week High
$233.60$88.50
52-Week Low
$145.57$17.70
Enterprise Value
$14.00B$9.16B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Victoria's Secret & Co

Victoria's Secret (VSXY) trades at $78.98, up 0.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and international growth momentum, particularly a 44.9% surge in Q1 2026 international sales, highlight operational improvements. The stock shows recovering profitability with a net income margin of 3.12% and robust ROE of 29.41%, though valuation metrics like a P/E of 31.47 suggest premium pricing relative to earnings.

The outlook remains positive with a consensus price target of $88.56 implying 12% upside, driven by innovation and global expansion. Risks include competitive pressures and reliance on margin recovery. Institutional sentiment is favorable with no sell ratings, but investors should monitor execution on growth initiatives and macroeconomic impacts on consumer spending.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Victoria's Secret & Co

Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.

Read more on VSXY